Evolution of core archetypal phenotypes in progressive high grade serous ovarian cancer.
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
24 05 2021
24 05 2021
Historique:
received:
06
10
2020
accepted:
08
04
2021
entrez:
25
5
2021
pubmed:
26
5
2021
medline:
16
6
2021
Statut:
epublish
Résumé
The evolution of resistance in high-grade serous ovarian cancer (HGSOC) cells following chemotherapy is only partially understood. To understand the selection of factors driving heterogeneity before and through adaptation to treatment, we profile single-cell RNA-sequencing (scRNA-seq) transcriptomes of HGSOC tumors collected longitudinally during therapy. We analyze scRNA-seq data from two independent patient cohorts to reveal that HGSOC is driven by three archetypal phenotypes, defined as oncogenic states that describe the majority of the transcriptome variation. Using a multi-task learning approach to identify the biological tasks of each archetype, we identify metabolism and proliferation, cellular defense response, and DNA repair signaling as consistent cell states found across patients. Our analysis demonstrates a shift in favor of the metabolism and proliferation archetype versus cellular defense response archetype in cancer cells that received multiple lines of treatment. While archetypes are not consistently associated with specific whole-genome driver mutations, they are closely associated with subclonal populations at the single-cell level, indicating that subclones within a tumor often specialize in unique biological tasks. Our study reveals the core archetypes found in progressive HGSOC and shows consistent enrichment of subclones with the metabolism and proliferation archetype as resistance is acquired to multiple lines of therapy.
Identifiants
pubmed: 34031395
doi: 10.1038/s41467-021-23171-3
pii: 10.1038/s41467-021-23171-3
pmc: PMC8144406
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
3039Subventions
Organisme : NCI NIH HHS
ID : U54 CA209978
Pays : United States
Références
Nat Rev Cancer. 2015 Nov;15(11):668-79
pubmed: 26493647
Cancer Sci. 2017 Apr;108(4):719-731
pubmed: 28165651
Cold Spring Harb Perspect Biol. 2013 Sep 01;5(9):
pubmed: 24003211
Genome Res. 2018 Aug;28(8):1217-1227
pubmed: 29898899
Lancet Oncol. 2011 Nov;12(12):1169-74
pubmed: 21742554
Eur J Cancer. 2020 Feb;126:125-135
pubmed: 31927213
Ann Oncol. 2015 Jan;26(1):64-70
pubmed: 25319062
Nucleic Acids Res. 2016 Sep 19;44(16):e131
pubmed: 27270079
Nat Immunol. 2019 Feb;20(2):163-172
pubmed: 30643263
Arch Gynecol Obstet. 2014 Nov;290(5):839-42
pubmed: 25082067
Bioinformatics. 2014 Apr 1;30(7):923-30
pubmed: 24227677
J Stat Softw. 2010;33(1):1-22
pubmed: 20808728
Genome Med. 2018 Oct 31;10(1):81
pubmed: 30382883
Nat Rev Cancer. 2018 Nov;18(11):696-705
pubmed: 30293088
Nat Methods. 2015 Mar;12(3):233-5, 3 p following 235
pubmed: 25622107
BMC Genomics. 2013 Sep 20;14:632
pubmed: 24053356
Nat Biotechnol. 2013 Mar;31(3):213-9
pubmed: 23396013
Cancer Metastasis Rev. 2011 Mar;30(1):141-51
pubmed: 21298574
Bioinformatics. 2017 Apr 15;33(8):1210-1215
pubmed: 28052928
Cancer Res. 2004 Nov 1;64(21):7678-81
pubmed: 15520168
BMC Bioinformatics. 2013 Aug 10;14:244
pubmed: 23937229
Nature. 2015 May 28;521(7553):489-94
pubmed: 26017449
Curr Opin Obstet Gynecol. 2017 Feb;29(1):26-34
pubmed: 27898521
Gynecol Oncol. 2013 Dec;131(3):772-9
pubmed: 24125749
Cancer Metastasis Rev. 2016 Dec;35(4):645-654
pubmed: 27878502
Bioinformatics. 2011 Jun 15;27(12):1739-40
pubmed: 21546393
J Pathol. 2010 May;221(1):49-56
pubmed: 20229506
Hematol Oncol Clin North Am. 2018 Dec;32(6):983-996
pubmed: 30390769
FEBS J. 2017 Oct;284(19):3132-3144
pubmed: 28444969
Nat Commun. 2019 Jan 9;10(1):95
pubmed: 30626865
Front Chem. 2015 Jun 02;3:35
pubmed: 26082923
Mol Cancer Ther. 2015 Oct;14(10):2260-9
pubmed: 26227489
Pharmacol Ther. 2015 Jun;150:33-46
pubmed: 25595324
Cell. 2016 Jul 28;166(3):755-765
pubmed: 27372738
Cell Cycle. 2009 Oct 15;8(20):3243-5
pubmed: 19806017
Genome Biol. 2016 Aug 24;17(1):178
pubmed: 27557938
Nat Rev Cancer. 2020 Apr;20(4):247-257
pubmed: 32094544
Science. 2012 Jun 1;336(6085):1157-60
pubmed: 22539553
Gynecol Oncol. 1990 Sep;38(3):340-2
pubmed: 2227545
Science. 2014 Jun 20;344(6190):1396-401
pubmed: 24925914
Nat Commun. 2017 Nov 1;8(1):1231
pubmed: 29093439
Ann Transl Med. 2019 Dec;7(Suppl 8):S299
pubmed: 32016018
Nat Rev Genet. 2009 May;10(5):336-42
pubmed: 19337290
Sci Rep. 2017 Aug 18;7(1):8760
pubmed: 28821788
Nat Biotechnol. 2018 Jun;36(5):411-420
pubmed: 29608179
Nature. 2012 Sep 6;489(7414):57-74
pubmed: 22955616
Cell Syst. 2015 Dec 23;1(6):417-425
pubmed: 26771021
Nat Commun. 2017 May 05;8:15081
pubmed: 28474673
Front Immunol. 2017 Jan 26;8:29
pubmed: 28184222
Mol Biol Int. 2014;2014:852748
pubmed: 25276427
Mol Cell Biol. 2004 May;24(10):4438-47
pubmed: 15121862
Nat Commun. 2019 Mar 20;10(1):1295
pubmed: 30894541
Nat Commun. 2018 Jan 18;9(1):284
pubmed: 29348443
Nat Commun. 2019 Aug 29;10(1):3908
pubmed: 31467286
J Immunol Res. 2014;2014:326593
pubmed: 24872956
Fly (Austin). 2012 Apr-Jun;6(2):80-92
pubmed: 22728672
Cell Signal. 2011 Feb;23(2):317-23
pubmed: 20727968
Cell. 2017 Feb 9;168(4):629-643
pubmed: 28187285
Oncotarget. 2015 Mar 30;6(9):6915-30
pubmed: 25762632
BMC Genomics. 2016 Nov 7;17(1):880
pubmed: 27821060
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Trends Cancer. 2018 Feb;4(2):110-118
pubmed: 29458961
Nat Med. 2013 Nov;19(11):1438-49
pubmed: 24202396
Mol Clin Oncol. 2013 Jan;1(1):3-11
pubmed: 24649114
Cancers (Basel). 2019 Jun 17;11(6):
pubmed: 31213009
BMC Bioinformatics. 2013 Jan 16;14:7
pubmed: 23323831
Genes Cancer. 2018 May;9(5-6):155-175
pubmed: 30603053
N Engl J Med. 2018 Dec 27;379(26):2495-2505
pubmed: 30345884
Proc Natl Acad Sci U S A. 2014 Nov 4;111(44):E4726-35
pubmed: 25339441
Nat Methods. 2018 Aug;15(8):591-594
pubmed: 30013048
Cell. 2019 Jun 13;177(7):1888-1902.e21
pubmed: 31178118
Nat Rev Cancer. 2013 Dec;13(12):883-92
pubmed: 24213474
Cell. 2017 Dec 14;171(7):1611-1624.e24
pubmed: 29198524
Nat Cell Biol. 2018 Dec;20(12):1349-1360
pubmed: 30482943
Cancer Res. 2019 Jul 1;79(13):3294-3305
pubmed: 31101765
Genome Res. 2018 Apr;28(4):581-591
pubmed: 29535149
J Clin Invest. 2007 May;117(5):1137-46
pubmed: 17476343
Obstet Gynecol. 2015 Sep;126(3):491-497
pubmed: 26244529
Cancer. 2014 Nov 15;120(22):3446-56
pubmed: 24948110
Annu Rev Genet. 2020 Nov 23;54:189-211
pubmed: 32867542
Front Immunol. 2018 May 04;9:847
pubmed: 29780381
Int J Gynaecol Obstet. 2012 Oct;119 Suppl 2:S118-29
pubmed: 22999503
Nat Methods. 2013 Nov;10(11):1081-2
pubmed: 24037244
Nat Genet. 2017 Jun;49(6):856-865
pubmed: 28436987